82 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748888 Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
MELEXIS NV IEPER 2019 Q4 - Results - Earnings Call Presentation https://seekingalpha.com/article/4321582-melexis-nv-ieper-2019-q4-results-earnings-call-presentation?source=feed_all_articles Feb 05, 2020 - The following slide deck was published by MELEXIS NV IEPER in conjunction with their 2019 Q4 earnings call.
Novartis International AG (NVS) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/02/05/novartis-international-ag-nvs-q4-2019-earnings-cal.aspx?source=iedfolrf0000001 Feb 05, 2020 - NVS earnings call for the period ending December 31, 2019.
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat http://www.zacks.com/stock/news/754291/alnylams-alny-q4-earnings-miss-estimates-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-754291 Feb 07, 2020 - Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
Regeneron Reports Positive Eylea Data From Late-Stage Study http://www.zacks.com/stock/news/758360/regeneron-reports-positive-eylea-data-from-late-stage-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-758360 Feb 10, 2020 - Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance http://www.zacks.com/stock/news/760081/gileads-bla-for-car-t-cell-therapy-gets-fda-acceptance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-760081 Feb 11, 2020 - The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
Arcadis NV 2019 Q4 - Results - Earnings Call Presentation https://seekingalpha.com/article/4323907-arcadis-nv-2019-q4-results-earnings-call-presentation?source=feed_all_articles Feb 13, 2020 - The following slide deck was published by Arcadis NV in conjunction with their 2019 Q4 earnings call.
Arcadis NV (ARCVF) CEO Peter Oosterveer on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4324282-arcadis-nv-arcvf-ceo-peter-oosterveer-on-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts Feb 14, 2020 - Arcadis NV (OTCPK:ARCVF) Q4 2019 Earnings Conference Call February 13, 2020 4:00 AM ET Company Participants Jurgen Pullens - Director of Investor Relations Peter Oosterveer - Chief Executive Officer S
Telenet Group Holding NV (TLGHF) CEO John Porter on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4324299-telenet-group-holding-nv-tlghf-ceo-john-porter-on-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts Feb 14, 2020 - Telenet Group Holding NV (OTCPK:TLGHF) Q4 2019 Results Conference Call February 12, 2020 09:00 AM ET Company Participants Rob Goyens - Investor Relations John Porter - Chief Executive Officer Erik den
Yandex NV (YNDX) on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4324334-yandex-nv-yndx-on-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts Feb 14, 2020 - Yandex NV (NASDAQ:YNDX) Q4 2019 Earnings Conference Call February 14, 2020, 08:00 ET Company Participants Katya Zhukova - IR Director Tigran Khudaverdyan - Deputy CEO & Director Gregory Abovsky -

Pages: 1...3456789

<<<Page 8